Relative contribution of risk factors/co-morbidities to heart failure pathogenesis: interaction with ejection fraction

被引:5
作者
Giamouzis, Grigorios [1 ]
Xanthopoulos, Andrew [1 ]
Papamichalis, Michail [1 ]
Chroub-Papavaiou, Artemis-Nantia [1 ,2 ]
Pantziou, Aikaterini [1 ,3 ]
Simou, Anthi [1 ]
Dimos, Apostolos [1 ]
Bourazana, Angeliki [1 ]
Skoularigis, John [1 ]
Triposkiadis, Filippos [1 ]
机构
[1] Gen Univ Hosp Larissa, Dept Cardiol, POB 1425, Larisa 41110, Greece
[2] Papageorgiou Gen Univ Hosp, Thessaloniki, Greece
[3] Gen Hosp Volos, Dept Cardiol, Volos, Greece
来源
ESC HEART FAILURE | 2020年 / 7卷 / 06期
关键词
Heart Failure; Morbidity; Co-morbidity; Coexisting disease; Hypertension; Myocardial infarction; Atrial fibrillation; Ejection fraction; NONCARDIAC COMORBIDITIES; CO-MORBIDITIES;
D O I
10.1002/ehf2.12975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non-cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF patients with a single coexisting morbidity, stratified by left ventricular ejection fraction (LVEF) categories, as a measure of the relative contribution of each co-morbidity to the pathogenesis of HF. Methods and results This is a prospective, observational study, in which unselected ambulatory patients with chronic HF visiting the HF clinic of a tertiary university hospital from January 2016 to January 2019 were classified according to baseline LVEF into three groups: (i) LVEF < 40%, (ii) LVEF = 40-49%, and (iii) LVEF >= 50% and then evaluated for various coexisting morbidities. Overall, 1064 patients (age 73.4 +/- 12.1 years, male gender 57.7%, LVEF 43.6 +/- 13.9, N-terminal pro-brain natriuretic peptide 2187 +/- 710 ng/L, and estimated glomerular filtration rate 67.2 +/- 25 mL/min/1.73 m(2)) were recruited in this study. Of these, 361 (33.9%) had an LVEF < 40%, 247 (23.2%) an LVEF = 40-49%, and 456 (42.9%) an LVEF >= 50%. There were 90 (8.5%) HF patients with a single coexisting morbidity, 33 (36.7%) with LVEF >= 50%, 27 (30.0%) with LVEF = 40-49%, and 30 (33.3%) with LVEF < 40%. Among these patients, those with LVEF >= 50% suffered mostly from hypertension (85.7%), whereas the second most common coexisting morbidity was atrial fibrillation (AF) (9.5%). HF patients with LVEF = 40-49% usually suffered from hypertension (35.7%), AF (28.6%), or myocardial infarction (MI) (21.4%). Finally, HF patients with LVEF < 40% usually suffered from MI (30.8%), AF (30.8%), or hypertension (15.4%). Conclusions Hypertension is strongly associated with the development of HF with low, intermediate, or near-normal/normal LVEF whereas a history of MI or AF with HF with a low or an intermediate LVEF.
引用
收藏
页码:4399 / 4403
页数:5
相关论文
共 50 条
  • [31] Chronic Heart Failure in Ambulatory Outpatients and the Impact of Multiple Co-Morbidities on Survival
    Arnold, J. Malcolm
    Ignaszewski, Andrew
    Howlett, Jonathan
    Leblanc, Marie-Helene
    Liu, Peter
    Kaan, Annemarie
    Zieroth, Shelley
    Baker, Sandy
    Hanzal, Djilali
    Marchiori, Gord
    CIRCULATION, 2011, 124 (21)
  • [32] Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction
    Pandey, Ambarish
    Omar, Wally
    Ayers, Colby
    LaMonte, Michael
    Klein, Liviu
    Allen, Norrina B.
    Kuller, Lewis H.
    Greenland, Philip
    Eaton, Charles B.
    Gottdiener, John S.
    Lloyd-Jones, Donald M.
    Berry, Jarett D.
    CIRCULATION, 2018, 137 (17) : 1814 - +
  • [33] Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors
    Kaur, Gurleen
    Lau, Emily
    WOMENS HEALTH, 2022, 18
  • [34] Prognostic factors in the heart failure with reduced ejection fraction
    Eyuboglu, Mehmet
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 235 : 187 - 187
  • [35] Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?
    Konstantinou, Dimitrios M.
    Karvounis, Haralambos
    Giannakoulas, George
    CARDIOLOGY, 2016, 134 (03) : 311 - 319
  • [36] History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction
    Oluleye, Oludamilola W.
    Rector, Thomas S.
    Win, Sithu
    McMurray, John J. V.
    Zile, Michael R.
    Komajda, Michel
    McKelvie, Robert S.
    Massie, Barry
    Carson, Peter E.
    Anand, Inder S.
    CIRCULATION-HEART FAILURE, 2014, 7 (06) : 960 - 966
  • [37] Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding
    Schrutka, Lore
    Seirer, Benjamin
    Duca, Franz
    Binder, Christina
    Dalos, Daniel
    Kammerlander, Andreas
    Aschauer, Stefan
    Koller, Lorenz
    Benazzo, Alberto
    Agibetov, Asan
    Gwechenberger, Marianne
    Hengstenberg, Christian
    Mascherbauer, Julia
    Bonderman, Diana
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [38] Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction
    Gaziano, Liam
    Cho, Kelly
    Djousse, Luc
    Schubert, Petra
    Galloway, Ashley
    Ho, Yuk-Lam
    Kurgansky, Katherine
    Gagnon, David R.
    Russo, John P.
    Di Angelantonio, Emanuele
    Wood, Angela M.
    Danesh, John
    Gaziano, John Michael
    Butterworth, Adam S.
    Wilson, Peter W. F.
    Joseph, Jacob
    ESC HEART FAILURE, 2022, 8 (06): : 4893 - 4903
  • [39] Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
    Chen, Min
    Li, Wentao
    Ran, Qin
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01):
  • [40] Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction
    O'Neal, Wesley T.
    Sandesara, Pratik B.
    Samman-Tahhan, Ayman
    Kelli, Heval M.
    Hammadah, Muhammad
    Soliman, Elsayed Z.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (11) : 1212 - 1219